Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ninjinyoeito for Prevention of Paclitaxel-Induced Peripheral Neuropathy in Gynecologic Cancers
jRCTs041260060Not yet recruiting
- Sponsor
- Fujita Health University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ninjinyoeito in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Fujita Health University. Primary endpoints: Incidence of CTCAE Grade ≥2 peripheral sensory neuropathy and Incidence of CTCAE Grade ≥2 peripheral motor neuropathy. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ninjinyoeito
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCTs041260060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260060.